New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG)
about
Treatment of relapsed and refractory multiple myelomaNotch signaling deregulation in multiple myeloma: A rational molecular targetMolecular Classification and Pharmacogenetics of Primary Plasma Cell Leukemia: An Initial Approach toward Precision MedicineTargeted therapy for HM1.24 (CD317) on multiple myeloma cellsNew criteria for response assessment: role of minimal residual disease in multiple myelomaSystematic approaches to identify E3 ligase substratesTowards Stratified Medicine in Plasma Cell MyelomaMagic year for multiple myeloma therapeutics: Key takeaways from the ASH 2015 annual meetingSpotlight on elotuzumab in the treatment of multiple myeloma: the evidence to dateTreatment of multiple myeloma with the immunostimulatory SLAMF7 antibody elotuzumabClinical use of proteasome inhibitors in the treatment of multiple myelomaNovel therapeutic strategies for multiple myelomaRecent advances in antimultiple myeloma drug development.Dose-escalation study of tabalumab with bortezomib and dexamethasone in Japanese patients with multiple myeloma.Immunotherapy in hematologic malignancies: past, present, and future.Implications of heterogeneity in multiple myeloma.Oral therapy for multiple myeloma: ixazomib arriving soon.Gene expression profile alone is inadequate in predicting complete response in multiple myeloma.Whole-exome sequencing of primary plasma cell leukemia discloses heterogeneous mutational patterns.Silence of MCL-1 upstream signaling by shRNA abrogates multiple myeloma growth.Minimal residual disease in myeloma by flow cytometry: independent prediction of survival benefit per log reductionIn vivo molecular imaging of chemokine receptor CXCR4 expression in patients with advanced multiple myeloma.TM-233, a novel analog of 1'-acetoxychavicol acetate, induces cell death in myeloma cells by inhibiting both JAK/STAT and proteasome activities.The oncogenic transcription factor IRF4 is regulated by a novel CD30/NF-κB positive feedback loop in peripheral T-cell lymphoma.Profile of elotuzumab and its potential in the treatment of multiple myelomaClinical trial spots for cancer patients by tumour type: The cancer trials portfolio at clinicaltrials.gov.Haematological malignancies: at the forefront of immunotherapeutic innovation.Real-World Use of 3rd Line Therapy for Multiple Myeloma in Austria: An Austrian Myeloma Registry (AMR) Analysis of the Therapeutic Landscape and Clinical Outcomes prior to the Use of Next Generation Myeloma TherapeuticsInduction of potent NK cell-dependent anti-myeloma cytotoxic T cells in response to combined mapatumumab and bortezomib.Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myelomaVascular endothelial growth factor as a predictive marker for POEMS syndrome treatment response: retrospective cohort study.The outcomes of newly diagnosed elderly multiple myeloma patients treated at a single U.S. institution.Bortezomib-related neuropathy may mask CNS relapse in multiple myeloma: A call for diligence.Risk stratification, treatment selection, and transplant eligibility in multiple myeloma: a qualitative study of the perspectives and self-reported practices of oncologists.Bortezomib-induced heat shock response protects multiple myeloma cells and is activated by heat shock factor 1 serine 326 phosphorylation.Evaluation of in vitro effects of various targeted drugs on plasma cells and putative neoplastic stem cells in patients with multiple myeloma.Potent in vitro and in vivo effects of polyclonal anti-human-myeloma globulins.An analysis of the safety profile of proteasome inhibitors for treating various cancers.T cell-based targeted immunotherapies for patients with multiple myeloma.Advances in multiple myeloma therapy during two past decades.
P2860
Q26749180-B5ECF64E-A2CD-44E1-82B4-D7054248FF99Q26797283-32239F45-BC72-418A-8E58-D9D998DDA42EQ26799238-BB5005FB-93C4-4D9F-BEA9-99AA43D99009Q27026161-228F107D-E882-42E5-97E7-FA790CB7103EQ27027512-46A2B618-B5B2-455E-A3C2-751AE8487B28Q28068398-D3A6B7C9-3A4A-4FFF-83D4-739DA711788CQ28074994-3BF03522-B537-4149-A4FC-51351EE9A754Q28075816-91BDCF52-AAD4-4BE2-A7DB-B10EFF139980Q28076147-E5E133B0-6D26-4ADA-954F-9A5221771914Q28078993-D7C28BBC-D35B-4752-9BD6-8F86E6D3502EQ28080999-BB728FC3-0297-4FBB-A4AE-DC9A55696C17Q28081590-B1F76343-CE94-4069-A7A1-C48BF848963DQ33416297-15320761-09F0-402D-AD32-991244EBD8E8Q33433447-3E98DE38-D4DA-4A14-BB8C-C4B26B77B002Q33593865-2E05FE4B-51A3-4852-9B8D-ADF684712BE3Q33914824-039D4E00-C87C-40D7-B323-2D2721B8ED28Q34047916-D585CFC5-6B43-4211-87A3-280EC0B4C686Q34345502-FB122350-FB90-4810-BECC-CC9BB2BA9D0CQ34479418-25ED6169-D9EC-4C8B-BB39-37F337E85A4DQ34566043-D0C092E2-A23D-4D8C-9A41-CBC606225848Q35222117-32C50377-02CD-49AD-9F88-1116895E0819Q35483867-62C09E5E-72E8-430D-BE17-7DEB4FC7F529Q35538460-63543E44-EACD-419F-AB06-1B496851B163Q35607281-6DF26464-C9A9-4D05-BDFC-A457A26071F8Q35628678-F57C8064-4679-4721-8EC2-C12737ACC57CQ35759905-2DDFE906-EAAB-49CA-8549-850101388A53Q35880618-3A7AF957-758C-4C8F-9BE6-55B9FD832D1EQ35944156-0FC3BA38-8C4B-479C-B2E2-E2B09794BE06Q36060298-9ECAEDF7-64B0-4CA1-9746-AD6087FB520CQ36213431-BE1A0A20-57E0-4B30-9124-41B06EC74A5FQ36302754-8539EE96-3F58-40B4-9272-B6F288A46B70Q36706899-73CCFE8A-A895-4488-BD24-AC0C46328D55Q37146294-23C32499-AF6D-4AF4-ABAB-3AC7ED3D292EQ37524970-E0268E6D-087E-42C0-8948-5CA54B77CD75Q37644930-D8A936B1-487D-45CA-9B62-7AF5232E2263Q37662286-4770AB49-24C1-47C1-B33F-A9F8D3F8C391Q37687119-5D6CBA53-ABF7-4E9B-9FA8-4187FD4FD6B2Q38227506-DA7412C0-216B-4224-B84E-06FC4B2038DAQ38246639-99FC6063-3159-4A18-8156-EF5E85091E28Q38248293-68B698A8-ED38-4E09-A3BC-4F20CBC4D7EC
P2860
New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG)
description
2014 nî lūn-bûn
@nan
2014 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի մարտին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
New drugs and novel mechanisms ...... l Myeloma Working Group (IMWG)
@ast
New drugs and novel mechanisms ...... l Myeloma Working Group (IMWG)
@en
New drugs and novel mechanisms ...... l Myeloma Working Group (IMWG)
@nl
type
label
New drugs and novel mechanisms ...... l Myeloma Working Group (IMWG)
@ast
New drugs and novel mechanisms ...... l Myeloma Working Group (IMWG)
@en
New drugs and novel mechanisms ...... l Myeloma Working Group (IMWG)
@nl
prefLabel
New drugs and novel mechanisms ...... l Myeloma Working Group (IMWG)
@ast
New drugs and novel mechanisms ...... l Myeloma Working Group (IMWG)
@en
New drugs and novel mechanisms ...... l Myeloma Working Group (IMWG)
@nl
P2093
P2860
P50
P3181
P356
P1433
P1476
New drugs and novel mechanisms ...... l Myeloma Working Group (IMWG)
@en
P2093
B G M Durie
I Turesson
J F S Miguel
J J Lahuerta
P2860
P2888
P304
P3181
P356
10.1038/LEU.2013.350
P407
P50
P577
2013-11-20T00:00:00Z
P6179
1051441977